Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).
All content for The Long Run with Luke Timmerman is the property of Timmerman Report and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).
Ep190: Neil Kumar on Building a Rare Disease Drug Company
The Long Run with Luke Timmerman
1 hour 13 minutes 12 seconds
1 month ago
Ep190: Neil Kumar on Building a Rare Disease Drug Company
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.
The Long Run with Luke Timmerman
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).
